JPRN-UMIN000006340已完成未知
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009) - Gefitinib vs Gefitinib plus chemotherapy for EGFR-mutated NSCLC (NEJ009)
orth-East Japan Study Group0 个研究点目标入组 345 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. NSCLC harboring T790M mutation 2. With massive effusion that require drainage 3. With symptomatic brain metastasis 4. With severe co-morbidities 5. With ineligible conditions judged by the attending physician
研究者
相似试验
已完成
3 期
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
已完成
3 期
Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene MutationsJPRN-C000000376EJ Gefitinib Study Group320
已完成
不适用
Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.Previously treated advanced lung adenocarcinomaJPRN-UMIN000030082West Japan Oncology Group561
已完成
3 期
Phase III study of gefitinib versus erlotinib in patients with previously treated lung adeno carcinomaPreviously treated lung adeno carcinomaJPRN-UMIN000002014West Japan Oncology Group560
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42